Table 1

Number of patients analyzed
Year 2005 2006 2007 2008 2009 2010
Diabetics patients followed up (1) 19,005 20,434 21,512 22,566 23,713 24,862
Patients analyzed 9,682 10,397 11,094 11,772 11,583 9,734
Monotherapy 5,792 59.8% 5,890 56.7% 6,080 54.8% 6,390 54.3% 6,065 52.4% 4,764
Double therapy 2,484 25.7% 2,815 27.1% 3,029 27.3% 3,147 26.7% 3,100 26.8% 2,770 28.5%
Triple therapy 355 3.7% 447 4.3% 551 5.0% 657 5.6% 730 6.3% 803 8.2%
Polytherapy 14 0.1% 28 0.3% 44 0.4% 66 0.6% 73 0.6% 98 1.0%
Insulinotherapy 1,037 10.7% 1,217 11.7% 1,390 12.5% 1,512 12.8% 1,615 13.9% 1,299 13.3%
Patients excluded 9,323 10,037 10,418 10,794 12,130 15,128
Lost to follow up 4,562 49% 4,877 49% 4,909 47% 4,821 45% 4,923 41% 4,418 29%
No pharmacological treatment 839 9% 1,152 11% 1,466 14% 1,719 16% 2,008 17% 1,610 11%
Pharmacological treatment with:
Discontinuation period 1,692 18% 1,846 18% 1,907 18% 1,959 18% 2,535 21% 6,411 42%
Non stationary period 1,255 13% 1,070 11% 1,086 10% 1,225 11% 1,432 12% 1,978 13%
Stage changes 975 10% 1,092 11% 1,050 10% 1,070 10% 1,232 10% 711 5%

Guelfucci et al.

Guelfucci et al. BMC Endocrine Disorders 2013 13:15   doi:10.1186/1472-6823-13-15

Open Data